These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 27705909)

  • 1. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
    Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
    Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
    Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib.
    Bochum S; Berger S; Martens UM
    Recent Results Cancer Res; 2018; 211():217-233. PubMed ID: 30069770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
    Ali R; Al-Kawaz A; Toss MS; Green AR; Miligy IM; Mesquita KA; Seedhouse C; Mirza S; Band V; Rakha EA; Madhusudan S
    Cancer Res; 2018 Dec; 78(24):6818-6827. PubMed ID: 30297533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
    van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
    Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
    Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
    Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A
    Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
    Jiang Y; Yam JC; Chu WK
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
    Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
    Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    Wang L; Yang C; Xie C; Jiang J; Gao M; Fu L; Li Y; Bao X; Fu H; Lou L
    Cancer Sci; 2019 Mar; 110(3):1064-1075. PubMed ID: 30663191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
    Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
    J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
    Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
    Ghosh R; Roy S; Kamyab J; Danzter F; Franco S
    DNA Repair (Amst); 2016 Sep; 45():56-62. PubMed ID: 27373144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.